Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Merck
Johnson and Johnson
Harvard Business School
McKinsey

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

OXTELLAR XR Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Oxtellar Xr patents expire, and what generic alternatives are available?

Oxtellar Xr is a drug marketed by Supernus Pharms and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has fourteen patent family members in ten countries.

The generic ingredient in OXTELLAR XR is oxcarbazepine. There are twenty-one drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.

US ANDA Litigation and Generic Entry Outlook for Oxtellar Xr

A generic version of OXTELLAR XR was approved as oxcarbazepine by GLENMARK PHARMS LTD on October 9th, 2007.

  Start Trial

Drug patent expirations by year for OXTELLAR XR
Drug Prices for OXTELLAR XR

See drug prices for OXTELLAR XR

Recent Clinical Trials for OXTELLAR XR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dauten Family Center for Bipolar Treatment Innovation, Massachusetts Gen HospitalPhase 4
Collaborative Care Initiative, LLCPhase 4
ParexelPhase 3

See all OXTELLAR XR clinical trials

Pharmacology for OXTELLAR XR
Paragraph IV (Patent) Challenges for OXTELLAR XR
Tradename Dosage Ingredient NDA Submissiondate
OXTELLAR XR TABLET, EXTENDED RELEASE;ORAL oxcarbazepine 202810 2013-04-12
OXTELLAR XR TABLET, EXTENDED RELEASE;ORAL oxcarbazepine 202810 2013-03-20

US Patents and Regulatory Information for OXTELLAR XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No   Start Trial   Start Trial   Start Trial
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-002 Oct 19, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-003 Oct 19, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Merck
Johnson and Johnson
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.